The FDA approved selinexor (Xpovio, Karyopharm) in combination with bortezomib and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy.
DECEMBER 22, 2020
DECEMBER 22, 2020
The FDA approved selinexor (Xpovio, Karyopharm) in combination with bortezomib and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy.